Tag Archives: IPF

September, 2018

August, 2018

November, 2017

October, 2017

August, 2017

  • 9 August

    FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study

    SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). Pamrevlumab is a proprietary, first-in-class, anti-connective tissue growth factor (CTGF) antibody being …

May, 2017

June, 2016

March, 2015

  • 17 March

    Galapagos and Janssen End Inflammation Alliance

    Galapagos NV and Janssen Pharmaceutica NV of Johnson & Johnson have ended their eight-year alliance to develop anti-inflammatory drugs. The companies originally entered into a worldwide multi-target alliance in October 2007, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA), a deal which provided Galapagos …